A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer

The mammalian target of rapamycin (mTOR) plays a critical role in promoting tumor cell growth and is frequently activated in breast cancer. In preclinical studies, the antitumor activity of mTOR inhibitors is attenuated by feedback up-regulation of AKT mediated in part by Insulin-like growth factor...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast Cancer Res Treat
Autors principals: Ma, Cynthia X., Suman, Vera J., Goetz, Matthew, Haluska, Paul, Moynihan, Timothy, Nanda, Rita, Olopade, Olufunmilayo, Pluard, Timothy, Guo, Zhanfang, Chen, Helen X., Erlichman, Charles, Ellis, Matthew J., Fleming, Gini F.
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4517667/
https://ncbi.nlm.nih.gov/pubmed/23605083
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-013-2528-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars